ESMO 2018 | Olaparib considerably increases PFS in ovarian cancer

Domenica Lorusso • 18 Jan 2019

ESMO 2018

Gynecological Cancer Ovarian Cancer Olaparib

SOLO-1

Domenica Lorusso, MD, PhD, of the IRCCS National Cancer Institute, Milan, Italy, gives an overview of the SOLO-1 trial (NCT01844986); evaluating maintenance monotherapy with olaparib following chemotherapy in newly-diagnosed patients with BRCA-mutated ovarian cancer. Dr Lorusso suggests that significant increases in PFS, when compared to the placebo, may indicate a curative potential or at least long-term benefit of the treatment in the first-line setting. She also calls for BRCA mutation screening, a response predictor for this agent, at the point of ovarian cancer diagnosis. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.